Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Retained Earnings came in at -$1.5 billion in Q1 2026, down 47.33% year-on-year from -$2.9 billion in Q1 2025, and down 9.02% quarter-over-quarter from -$1.4 billion in Q4 2025.
Crinetics Pharmaceuticals has reported Retained Earnings for 10 years, with the latest figure at -$1.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 47.33% year-over-year to -$1.5 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.5 billion (down 47.33% YoY), and the FY2025 full-year result was -$1.4 billion, down 147288.68% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$1.4 billion in the prior quarter.
- The five-year high for Retained Earnings was $2.0 million in Q3 2024, with the low at -$1.5 billion in Q1 2026.
- Average Retained Earnings over 5 years is -$602.6 million, with a median of -$485.2 million recorded in 2023.
- Year-over-year, Retained Earnings jumped 100.34% in 2024 and plunged 147288.68% in 2025.
- Tracing CRNX's Retained Earnings over 5 years: stood at -$439.2 million in 2022, then soared by 100.22% to $977000.0 in 2023, then decreased by 1.43% to $963000.0 in 2024, then sank by 147288.68% to -$1.4 billion in 2025, then fell by 9.02% to -$1.5 billion in 2026.
- The last three Retained Earnings figures came in at -$1.5 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -1.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.55 Bn |
| Dec 31, 2025 | -1.42 Bn |
| Sep 30, 2025 | -1.29 Bn |
| Jun 30, 2025 | -1.20 Bn |
| Mar 31, 2025 | -1.05 Bn |
| Dec 31, 2024 | 963,000.00 |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | -794.69 Mn |
| Mar 31, 2024 | -720.60 Mn |
| Dec 31, 2023 | 977,000.00 |
| Sep 30, 2023 | -593.60 Mn |
| Jun 30, 2023 | -1.71 Mn |
| Mar 31, 2023 | -485.17 Mn |
| Dec 31, 2022 | -439.17 Mn |
| Sep 30, 2022 | -394.18 Mn |
| Jun 30, 2022 | -3.62 Mn |
| Mar 31, 2022 | -309.90 Mn |
| Dec 31, 2021 | -382,000.00 |
| Sep 30, 2021 | -244.46 Mn |
| Jun 30, 2021 | -216.60 Mn |
| Mar 31, 2021 | -190.50 Mn |
| Dec 31, 2020 | -167.61 Mn |
| Sep 30, 2020 | -146.00 Mn |
| Jun 30, 2020 | -127.65 Mn |
| Mar 31, 2020 | 167,000.00 |
| Dec 31, 2019 | 148,000.00 |
| Sep 30, 2019 | 198,000.00 |
| Jun 30, 2019 | -64.82 Mn |
| Mar 31, 2019 | 145,000.00 |
| Dec 31, 2018 | 61,000.00 |
| Sep 30, 2018 | -34.89 Mn |
| Jun 30, 2018 | -27.30 Mn |
| Dec 31, 2017 | -16.27 Mn |